ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE
The remodelling of the heart that occurs after myocardial infarction independently contributes to heart failure (HF) progression. In a rapidly growing patient population with chronic HF, new, safe, and effective therapeutic strategies are needed. Recently, injectable biomaterial-based therapies have...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2018-01-01
|
| Series: | European Medical Journal Innovations |
| Subjects: | |
| Online Access: | https://www.emjreviews.com/innovations/article/editors-pick-algisyl-injections-an-innovative-strategy-for-patients-with-advanced-heart-failure/ |
| _version_ | 1818020362342891520 |
|---|---|
| author | Katarzyna Rygiel |
| author_facet | Katarzyna Rygiel |
| author_sort | Katarzyna Rygiel |
| collection | DOAJ |
| description | The remodelling of the heart that occurs after myocardial infarction independently contributes to heart failure (HF) progression. In a rapidly growing patient population with chronic HF, new, safe, and effective therapeutic strategies are needed. Recently, injectable biomaterial-based therapies have been gaining interest, especially for patients post myocardial infarction who have had complications due to advanced HF. One such intervention, based on Algisyl® (LoneStar Heart Inc., Irvine, California, USA) injections, has been examined in the recent prospective, randomised, controlled AUGMENT-HF clinical trial. This paper briefly presents characteristics of Algisyl, an injectable calcium alginate hydrogel; describes a minimally invasive myoplasty procedure for the insertion of Algisyl implants; and provides a concise overview of the design, methods, and results of the AUGMENT-HF study. This paper focusses on the promising findings that Algisyl, in addition to standard medical therapy, was more effective than the standard medical therapy alone for providing sustained 6-month and 1-year benefits in exercise capacity and symptomatic improvement among patients with advanced HF. In addition, this report discusses some implications and challenges relevant to the AUGMENT-HF trial, and addresses the importance of a blind study design for further studies in this field. Moreover, this paper highlights future perspectives for examining the Algisyl implants, aimed at functional clinical outcomes, quality of life, and safety issues, prior to a possible implementation of this strategy into clinical practice. |
| first_indexed | 2024-04-14T08:05:02Z |
| format | Article |
| id | doaj.art-2cb943b24e7a4a31a51588ef75e6468d |
| institution | Directory Open Access Journal |
| issn | 2513-8634 |
| language | English |
| last_indexed | 2024-04-14T08:05:02Z |
| publishDate | 2018-01-01 |
| publisher | European Medical Journal |
| record_format | Article |
| series | European Medical Journal Innovations |
| spelling | doaj.art-2cb943b24e7a4a31a51588ef75e6468d2022-12-22T02:04:47ZengEuropean Medical JournalEuropean Medical Journal Innovations2513-86342018-01-01214449ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILUREKatarzyna Rygiel0Department of Environmental Medicine and Epidemiology, Medical University of Silesia (SUM), Zabrze, PolandThe remodelling of the heart that occurs after myocardial infarction independently contributes to heart failure (HF) progression. In a rapidly growing patient population with chronic HF, new, safe, and effective therapeutic strategies are needed. Recently, injectable biomaterial-based therapies have been gaining interest, especially for patients post myocardial infarction who have had complications due to advanced HF. One such intervention, based on Algisyl® (LoneStar Heart Inc., Irvine, California, USA) injections, has been examined in the recent prospective, randomised, controlled AUGMENT-HF clinical trial. This paper briefly presents characteristics of Algisyl, an injectable calcium alginate hydrogel; describes a minimally invasive myoplasty procedure for the insertion of Algisyl implants; and provides a concise overview of the design, methods, and results of the AUGMENT-HF study. This paper focusses on the promising findings that Algisyl, in addition to standard medical therapy, was more effective than the standard medical therapy alone for providing sustained 6-month and 1-year benefits in exercise capacity and symptomatic improvement among patients with advanced HF. In addition, this report discusses some implications and challenges relevant to the AUGMENT-HF trial, and addresses the importance of a blind study design for further studies in this field. Moreover, this paper highlights future perspectives for examining the Algisyl implants, aimed at functional clinical outcomes, quality of life, and safety issues, prior to a possible implementation of this strategy into clinical practice.https://www.emjreviews.com/innovations/article/editors-pick-algisyl-injections-an-innovative-strategy-for-patients-with-advanced-heart-failure/algisyl®clinical symptomsfunctional capacityheart failure (hf)safety |
| spellingShingle | Katarzyna Rygiel ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE European Medical Journal Innovations algisyl® clinical symptoms functional capacity heart failure (hf) safety |
| title | ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE |
| title_full | ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE |
| title_fullStr | ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE |
| title_full_unstemmed | ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE |
| title_short | ALGISYL® INJECTIONS: AN INNOVATIVE STRATEGY FOR PATIENTS WITH ADVANCED HEART FAILURE |
| title_sort | algisyl r injections an innovative strategy for patients with advanced heart failure |
| topic | algisyl® clinical symptoms functional capacity heart failure (hf) safety |
| url | https://www.emjreviews.com/innovations/article/editors-pick-algisyl-injections-an-innovative-strategy-for-patients-with-advanced-heart-failure/ |
| work_keys_str_mv | AT katarzynarygiel algisylinjectionsaninnovativestrategyforpatientswithadvancedheartfailure |